We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-22.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$402M
AUM Growth
-$164M
Cap. Flow
+$47.9M
Cap. Flow %
11.9%
Top 10 Hldgs %
62.89%
Holding
86
New
14
Increased
17
Reduced
23
Closed
25

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$55.3M
2
AMRN
Amarin Corp
AMRN
+$43M
3
TGTX icon
TG Therapeutics
TGTX
+$21.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$20.9M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$15.8M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$21.9M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$18.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16M
4
ENSG icon
The Ensign Group
ENSG
+$14M
5
SNY icon
Sanofi
SNY
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.24%
2 Miscellaneous 5.59%
3 Communication Services 2.07%
4 Financials 0.11%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.62M 0.9%
+106,385
New +$4.86M
IOVA icon
27
Iovance Biotherapeutics
IOVA
$3.63B
$2.7M 0.67%
+90,047
New +$2.39M
GNMK
28
DELISTED
GenMark Diagnostics, Inc
GNMK
$2.16M 0.54%
+524,257
New +$2.46M
CYTK icon
29
Cytokinetics
CYTK
$10B
$2.14M 0.53%
181,700
– –
CYH icon
30
Community Health Systems
CYH
$413M
$1.94M 0.48%
580,350
-14
-0% -$57
ALGN icon
31
PUT
Align Technology
ALGN
$11.2B
$1.74M 0.43%
+10,000
New +$2.39M
NVST icon
32
Envista
NVST
$4.36B
$1.63M 0.41%
109,212
-397,466
-78% -$10.2M
OXFD
33
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.59M 0.4%
172,193
-177,630
-51% -$2.48M
AGRX
34
DELISTED
Agile Therapeutics
AGRX
$1.32M 0.33%
356
-212
-37% -$1.22M
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.3M 0.32%
27,752
+6,300
+29% +$404K
ALBO
36
DELISTED
Albireo Pharma Inc
ALBO
$1.28M 0.32%
78,029
– –
AUTL
37
Autolus Therapeutics
AUTL
$623M
$1.26M 0.31%
+210,013
New +$1.94M
IMVT icon
38
Immunovant
IMVT
$8.51B
$1.2M 0.3%
76,866
– –
LQDA icon
39
Liquidia Corp
LQDA
$6.06B
$1.15M 0.29%
244,637
-39,466
-14% -$196K
HSKA
40
DELISTED
Heska Corp
HSKA
$1.15M 0.29%
20,771
– –
OTIC
41
DELISTED
Otonomy, Inc.
OTIC
$1.11M 0.28%
561,737
+11,072
+2% +$34.1K
DRNA
42
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.1M 0.27%
59,774
+41,100
+220% +$799K
TLGT
43
DELISTED
Teligent, Inc
TLGT
$1.08M 0.27%
386,290
-63,890
-14% -$259K
SCPH
44
DELISTED
scPharmaceuticals
SCPH
$980K 0.24%
132,419
-169,217
-56% -$1.23M
CYCN icon
45
Cyclerion Therapeutics
CYCN
$17.7M
$893K 0.22%
+16,857
New +$1.2M
AFMD
46
DELISTED
Affimed
AFMD
$886K 0.22%
56,080
-29,697
-35% -$707K
XENE icon
47
Xenon Pharmaceuticals
XENE
$5.81B
$812K 0.2%
71,591
-144,018
-67% -$2.05M
TARA icon
48
Protara Therapeutics
TARA
$226M
$747K 0.19%
+32,478
New +$946K
IFRX icon
49
InflaRx
IFRX
$329M
$747K 0.19%
195,488
-139,130
-42% -$515K
CARM
50
DELISTED
Carisma Therapeutics
CARM
$729K 0.18%
65,000
– –
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Eversept Partners held 86 positions worth $402M, down 29% from $566M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $47.9M of net new capital in Q1 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was HCA Healthcare: 101,000 shares worth $9.07M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was GSK, an estimated $21.9M trimmed.

  • Eversept Partners's largest Q1 2020 buy was HCA Healthcare: 101,000 shares worth $9.07M.
  • Eversept Partners added most to Zogenix, Inc. in Q1 2020, an estimated $55.3M increase.
  • Eversept Partners's biggest Q1 2020 reduction was GSK, cutting an estimated $21.9M.
  • Eversept Partners fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $18.3M.
  • Eversept Partners's ten largest holdings make up 63% of its $402M portfolio in Q1 2020.
  • Eversept Partners opened 14 new positions and closed 25 in Q1 2020.
  • Eversept Partners's portfolio value fell 29% quarter-over-quarter to $402M.

Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.